Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Ogivri 440
Beximco Pharmaceuticals Ltd.
Generic: Trastuzumab
Safety Advices
বাংলা
English
UNSAFE
Ogivri 440 may cause excessive drowsiness with alcohol.
CONSULT YOUR DOCTOR
Ogivri 440 is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
CONSULT YOUR DOCTOR
Ogivri 440 is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
CONSULT YOUR DOCTOR
It is not known whether Ogivri 440 alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
SAFE IF PRESCRIBED
Ogivri 440 is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Ogivri 440 may not be needed in these patients. Please consult your doctor.
CONSULT YOUR DOCTOR
There is limited information available on the use of Ogivri 440 in patients with liver disease. Please consult your doctor.
Medicine Overview of Ogivri 440mg/20ml Injection
Introduction
Ogivri 440 is used in the treatment of breast and stomach cancer. It works by killing the cancer cells by inhibiting HER2 (human epidermal growth factor receptor protein). Ogivri 440 is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It...
... Show moreUses of Ogivri 440
- Breast cancer
- Stomach cancer
Side effects of Ogivri 440
Common
- Anemia (low number of red blood cells)
- Chills
- Common cold
- Cough
- Decreased blood cells (red cells, white cells, and platelets)
- Diarrhea
- Fatigue
- Fever
- Headache
- Heart failure
- Infection
- Insomnia (difficulty in sleeping)
- Mucosal inflammation
- Nausea
- Rash
- Stomatitis (Inflammation of the mouth)
- Taste change
- Upper respiratory tract infection
- Weight loss
How to use Ogivri 440
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Ogivri 440 works
Ogivri 440 is a recombinant IgG1 monoclonal antibody. It works against the HER2 (human epidermal growth factor receptor protein) receptors which are responsible for the over-proliferation of cancer cells in breast cancer and stomach cancer cells. It destroys the cancer cells by inhibiting HER2. It also inhibits various cancer-causing downstream signaling pathways.
What if you forget to take Ogivri 440?
If you miss a dose of Ogivri 440, please consult your doctor.
Quick Tips
- It is given as an injection into your vein or under the skin, usually over 1 hour.
- Use effective contraception method to prevent pregnancy while taking this medicine and for 7 months after you stop the treatment.
- Your doctor will monitor your heart regularly while taking this medicine. Inform your doctor if you notice symptoms such as breathlessness, cough, shivering, swelling of legs and arm.
- Inform your doctor if you are pregnant, planning pregnancy or breastfeeding.
Brief Description
Indication
Breast cancer, Gastric cancer
Administration
IV Administration
Not for IV push or bolus administration
Administer initial IV infusion over 90 min
Subsequent weekly IV infusions may be administered over 30 min if prior infusions are well tolerated
Adult Dose
Intravenous Breast Cancer Adjuvant treatment Indicated for adjuvant treatment of HER-2 overexpressing breast cancer Administer during and following paclitaxel, docetaxel, or docetaxel/carboplatin 4 mg/kg IV over 90 minutes, THEN 2 mg/kg IV over 30 minutes qWeek during chemotherapy for the first 12 weeks (paclitaxel or docetaxel) or 18 weeks (docetaxel/carboplatin) One week following the last weekly dose administer at 6 mg/kg as an IV infusion over 30?90 min every three weeks As single agent within three wk following completion of multi-modality, anthracycline based chemotherapy regimens: Initial dose at 8 mg/kg as an IV infusion over 90 min; subsequent doses at...
... Show moreChild Dose
Safety and efficacy not established
Contraindication
Lactation (start only 6 mth after last dose of drug). Do not admin by rapid IV or bolus inj.
Mode of Action
Trastuzumab, a monoclonal antibody, has action directed against a cell surface protein produced by human epidermal growth factor receptor 2 (HER2). It inhibits proliferation of tumour cells that overexpress HER2 e.g. in 1/3 of breast cancer.
Precaution
Patient w/ pre-existing CV and pulmonary disease; extensive pulmonary tumour involvement. Pregnancy and lactation. Monitoring Parameters Monitor cardiac function prior and during treatment.
Lactation: not known if excreted in breast milk, discontinue nursing during treatment and for 6 months after last dose
Side Effect
>10%
Pain (47%),Asthenia (42%),Fever (36%),Nausea (33%),Chills (32%),Cough (26%),Headache (26%),Diarrhea (25%),Vomiting (23%),Abdominal pain (22%),Back pain (22%),Dyspnea (22%),Infection (20%),Rash (18%),Anorexia (14%),Insomnia (14%),Dizziness (13%)
1-10%
Flu-like syndrome (10%),Peripheral edema (10%),CHF (7%),Depression (6%),Tachycardia (5%),UTI (5%),Anemia (4%),Hypersensitivity (3%),Leukopenia (3%)
Potentially Fatal: Severe hypersensitivity (anaphylaxis) and infusion reactions; pulmonary events e.g. acute respiratory distress syndrome; cardiotoxicity. Neutropenia (especially when given with chemotherapy).
Interaction
Increased risk of severe cardiotoxicity with anthracyclines. Increased risk of leukopenia and anaemia in combination chemotherapy (e.g. paclitaxel). Paclitaxel may decrease the clearance of trastuzumab. Increased risk of bleeding with warfarin.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
